Zydus Cadila secures USFDA nod to market acne drug
The dug will be produced at the group’s Topical manufacturing facility at Ahmedabad in Gujarat, India. This combination medication, according to the pharma company, is used to treat
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will